1. Report Industry Investment Rating No relevant content provided. 2. Core Viewpoints of the Report - The convertible bond market is currently in a state of high sentiment. With the support of valuation, convertible bonds have outperformed underlying stocks, and the median price, 100 - yuan valuation, and convertible bond index are all at historical highs. The market shows a differentiated structure. For low - volatility fundamental and mid - to high - priced convertible bonds, trading may be better than allocation due to potential price - fluctuation risks. For high - elasticity fundamental and high - priced convertible bonds, they are the most elastic variety in the market, and their space is expected to expand further. Currently, with the continuous rise of risk preference, small - cap and low - rated convertible bonds may become the key areas for capital speculation, while high - rated and large - cap convertible bonds can focus on downward - revision games [4][5]. 3. Summary by Relevant Catalogs 3.1 Weekly View and Outlook - **Low - volatility and Mid - to High - priced Convertible Bonds**: Since 2025, the imbalance between supply and demand in the convertible bond market has led to strong performance of traditional low - priced convertible bonds. The median price of the whole market has been rising, and the premium rate of low - parity convertible bonds is at a historical high. Due to the lack of elasticity in the underlying stock fundamentals and strong call expectations, there may be price - fluctuation risks at high premium rates, so trading is preferred over allocation [4][5]. - **High - elasticity and High - priced Convertible Bonds**: These are traditional high - parity and high - priced convertible bonds with high volatility. In Q2 2025, their performance was relatively limited, and the valuation was not high, with strong call risks being a significant constraint. However, the underlying stock fundamentals are relatively good, and the support logic is clear. Since Q3, their elasticity has gradually been released. Even if a call notice is issued, the impact on the bond price is expected to be controllable in the context of sufficient liabilities. Currently, with the continuous rise of risk preference, small - cap and low - rated convertible bonds may be the focus of capital speculation, and high - rated and large - cap convertible bonds can focus on downward - revision games to find potential trading opportunities [4][5]. 3.2 Convertible Bond Valuation - This week, both convertible bonds and underlying stocks continued to rise, and the increase of convertible bonds exceeded that of underlying stocks. The valuation of convertible bonds was extremely strong. The 100 - yuan premium rate of the whole - market convertible bonds was 35%, with a single - week increase of 1.21%, and the latest quantile was at the 93.40% percentile since 2017. The valuation of both high - and low - rated convertible bonds increased by more than 1% this week. After removing outliers, the 100 - yuan valuations of high - and low - rated convertible bonds were both at extreme levels since 2017 [4][7]. - The convertible bond yield to maturity reached a new low since 2017, reporting - 6.27%. As of the latest data, the conversion premium rate index, pure - bond premium rate index, and yield to maturity were 42.08%, 43.32%, and - 6.27% respectively, with changes of - 0.27%, + 3.96%, and - 0.67% compared to last week, and their current quantile levels were at the 62.10%, 77.20%, and 0.00% percentiles since 2017 [4][9]. 3.3 Clause Tracking 3.3.1 Redemption - This week, convertible bonds such as Kaineng, Yaoshi, and Gaoce issued early redemption announcements. Currently, there are 24 convertible bonds that have issued call or maturity redemption announcements but have not been delisted, and the potential conversion or maturity balance of these non - delisted convertible bonds is 4.4 billion yuan. There are currently 41 convertible bonds in the redemption process, and 17 are expected to meet the redemption conditions next week. Also, 6 convertible bonds issued non - redemption announcements this week [4][14]. 3.3.2 Downward Revision - This week, Tianye and Huayang convertible bonds proposed downward revisions, and Jinneng, Lanfan, and Tian 23 announced downward revisions. Among them, Jinneng and Tian 23 convertible bonds were revised downward to the maximum, while Lanfan was not. As of the latest data, 136 convertible bonds are in the non - downward - revision interval, 23 cannot be revised downward due to net - asset constraints, 1 has triggered the condition but the stock price is still below the downward - revision trigger price without an announcement, 27 are accumulating downward - revision days, and 3 have issued downward - revision board proposals but have not yet held a general meeting of shareholders [4][20]. 3.3.3 Put Option - No convertible bonds issued put - option announcements this week. As of the latest data, 2 convertible bonds have issued put - option announcements, and 4 are accumulating put - option trigger days, among which 2 are in the non - downward - revision interval and 2 are accumulating downward - revision days [4][22]. 3.4 Primary Issuance - This week, Kaizhong convertible bonds issued an issuance announcement. As of now, Weidao and Kaizhong convertible bonds have been issued but have not yet determined their listing dates. There are currently 5 convertible bonds in the approval - registration progress, with a total issuance scale of 5.4 billion yuan, and 4 in the listing - committee approval progress, with a total issuance scale of 9 billion yuan [4][24].

Core Viewpoint - Kunming Pharmaceutical Group (600422.SH) reported a decline in both revenue and net profit for the first half of 2025, indicating challenges in its financial performance compared to the previous year [1][3]. Financial Performance - The company's total revenue for the first half of 2025 was 3.351 billion yuan, a decrease of 443 million yuan, representing an 11.68% year-on-year decline [1]. - The net profit attributable to shareholders was 198 million yuan, down by 72.91 million yuan, reflecting a 26.88% decrease compared to the same period last year [1]. - Operating cash flow showed a net inflow of 219 million yuan, which is a reduction of 62.44 million yuan, marking a 22.20% decline year-on-year [1]. Key Financial Ratios - The latest debt-to-asset ratio stood at 46.51%, an increase of 0.51 percentage points from the previous quarter and up 1.74 percentage points from the same period last year [3]. - The gross profit margin was reported at 39.85%, which is an increase of 2.94 percentage points from the previous quarter but a decrease of 1.25 percentage points year-on-year [3]. - Return on equity (ROE) was 3.79%, down by 0.47 percentage points compared to the same period last year [3]. Earnings and Efficiency Metrics - The diluted earnings per share were 0.26 yuan, a decrease of 0.10 yuan, reflecting a 27.78% decline year-on-year [4]. - The total asset turnover ratio was 0.27 times, down by 0.05 times from the previous year, indicating a 16.57% year-on-year decline [4]. - The inventory turnover ratio improved to 1.34 times, an increase of 0.16 times, representing a 13.82% year-on-year rise [4]. Shareholder Structure - The number of shareholders was reported at 39,400, with the top ten shareholders holding a total of 358 million shares, accounting for 47.33% of the total share capital [4]. - The largest shareholder is China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., holding 28.05% of the shares [4].

Group 1 - The core point of the article highlights the financing activities of Kunyu Pharmaceutical Group, indicating a net sell-off in recent trading days [1] - On August 15, Kunyu Pharmaceutical Group had a financing buy amount of 0.14 billion, ranking 1163rd in the two markets, with a financing repayment amount of 0.20 billion, resulting in a net sell of 5.49 million [1] - Over the last three trading days (August 13-15), the financing buy amounts were 0.31 billion, 0.16 billion, and 0.14 billion respectively [1] Group 2 - In terms of securities lending, on August 15, there were 0.06 thousand shares sold short, while 0.20 thousand shares were net bought [1]

Core Viewpoint - The company is navigating a challenging external environment while focusing on strategic reforms and innovations to enhance its competitive position in the pharmaceutical industry, particularly in the context of aging population and healthcare demands [3][5][6]. Company Overview - The company is engaged in the pharmaceutical industry, emphasizing traditional Chinese medicine and innovative drug development [3][10]. - The company has a strategic focus on becoming a leader in elderly health management and chronic disease management, leveraging its established brand and product resources [6][7]. Financial Performance - The company experienced a decline in revenue and net profit during the reporting period due to external challenges such as intensified competition and policy impacts [5]. - Despite the short-term performance pressure, the company is committed to long-term growth through strategic reforms and channel transformations [5][6]. Industry Analysis - The Chinese pharmaceutical industry is benefiting from a large population base, a broad domestic market, and increasing innovation capabilities, which enhance its international competitiveness [3]. - Recent government policies are supportive of innovative drug development, aiming to create a globally competitive ecosystem for the pharmaceutical industry [3][4]. Market Trends - The aging population is driving demand for healthcare services, creating a significant market opportunity for the company [6][7]. - The retail pharmaceutical sector is undergoing consolidation, with a shift towards online purchasing channels impacting traditional sales models [4][5]. Strategic Initiatives - The company is actively participating in national drug procurement programs to enhance its market presence and product accessibility [8][9]. - The company is focusing on brand enhancement and marketing strategies to strengthen its core product lines and expand its market reach [9][11]. Research and Development - The company is advancing its R&D efforts in the field of elderly health and chronic disease management, with a focus on natural and plant-based medicines [12]. - Several innovative drug projects are progressing, including those targeting ischemic stroke and non-alcoholic fatty liver disease, which are expected to meet significant clinical needs [12][13]. Global Expansion - The company is pursuing international market opportunities, having submitted numerous overseas registration applications and successfully obtaining product approvals in multiple countries [13]. - The company is also engaging in international collaborations to enhance its global footprint and contribute to global health initiatives [13].

（编辑 何成浩） 证券日报网讯 8月15日晚间，昆药集团发布公告称，2025年半年度公司实现营业收入3，351，347， 279.45元，同比下降11.68%；归属于上市公司股东的净利润为198，355，219.85元，同比下降26.88%。 ...

（文章来源：证券日报） 证券日报网讯 8月15日晚间，昆药集团发布公告称，公司拟聘任毕马威华振会计师事务所（特殊普通合 伙）为2025年度财务报表及内部控制审计机构。 ...

Core Insights - The company reported a revenue of 3.351 billion yuan and a net profit of 198 million yuan for the first half of 2025, with a non-recurring net profit of 151 million yuan [1] - The pharmaceutical manufacturing industry in China is facing a decline in both revenue and profit, with challenges in the traditional Chinese medicine sector despite supportive policies [1] - The company is undergoing a reform phase, focusing on the elderly health sector and deepening reforms to accumulate conditions for long-term development [1] Financial Performance - The company achieved a revenue of 3.351 billion yuan in the first half of 2025 [1] - The net profit attributable to shareholders was 198 million yuan, with a non-recurring net profit of 151 million yuan [1] - The overall operational status improved in the second quarter compared to the first quarter, with positive changes in business performance [1] Strategic Initiatives - The company is accelerating strategic collaboration in chronic disease management, integrating resources between Huaren Shenghuo and the 777 division [2] - The company is transitioning its sales model from decentralized control to a more centralized commercial system, expanding coverage to small and medium-sized chain and independent pharmacies [2] - The company launched a new product system under its core platform, Kunzhongyao 1381, focusing on various health categories [2] Innovation and R&D - The company is advancing its clinical research for the new drug KYAZ01-2011-020 for ischemic stroke and KYAH01-2018-111 for non-alcoholic fatty liver disease [3] - The company submitted 90 overseas registration applications and received approvals for 7 products in the first half of the year [3] - The sales volume of injectable blood stasis and soft capsules has seen rapid growth in the market [3]

Core Viewpoint - Kun Pharmaceutical Group reported a revenue of 3.351 billion yuan and a net profit of 198 million yuan for the first half of 2025, amidst a challenging environment for the pharmaceutical manufacturing industry in China [1] Financial Performance - The company achieved a revenue of 3.351 billion yuan in the first half of 2025, with a net profit attributable to shareholders of 198 million yuan and a net profit of 151 million yuan after deducting non-recurring items [1] - The overall operational status improved in the second quarter compared to the first quarter, indicating positive changes in the business [1] Strategic Initiatives - In the chronic disease management sector, the company is accelerating strategic collaboration and resource integration, particularly between Huaren Shenghuo and the 777 division [2] - The company is transitioning its sales model from decentralized control to a more centralized commercial system, expanding its coverage in small chain and independent pharmacies [2] - The launch of the new packaging for the 777 Xuesaitong soft capsules and community health events aims to enhance consumer recognition [2] Product Development - The company focuses on the "Kun Traditional Chinese Medicine 1381" platform to strengthen its brand positioning as a leader in premium traditional Chinese medicine [3] - Key products include Shenling Baizhu Powder and Shugan Granules, with marketing strategies targeting emotional health and digestive health [3] - A new product system has been launched, covering five categories and 24 products, focusing on kidney health, digestive health, women's health, respiratory health, and mental well-being [3] Research and Development - The company is committed to "healthy aging" as a core strategic direction, focusing on plant-based and natural medicines [4] - Ongoing clinical research includes a new drug for ischemic stroke and a new drug for non-alcoholic fatty liver disease, both of which are progressing through clinical trials [4] - The company is also advancing its pipeline of generic and improved new drugs to enhance its research capabilities [4] Global Expansion - The company submitted 90 overseas registration applications in the first half of 2025, with 7 products approved, and has gained market access in 15 countries for its Xuesaitong preparations [5] - The company received its first global fund procurement order for Dihydroartemisinin-Piperaquine tablets and held promotional events for the 777 Xuesaitong series in the US, Germany, and Vietnam [5] - Sales volumes for the injectable Xuesaitong (freeze-dried) and Lotaixue Xuesaitong soft capsules experienced rapid growth during the reporting period [5]

证券代码：600422 证券简称：昆药集团 公告编号：2025-041号 昆药集团股份有限公司十一届五次监事会决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 昆药集团股份有限公司（以下简称"昆药集团"、"公司"）于 2025 年 8 月 14 日 以现场+线上会议方式召开公司十一届五次监事会会议。会议通知以书面方式于 2025 年 8 月 4 日发出。会议由公司监事会主席钟江先生召集并主持，本次会议应参加表决 监事 5 人，实际参加表决 5 人，符合《公司法》和《公司章程》的规定。会议审议并 通过了以下决议： 公司半年度报告编制和审议程序符合法律、法规、公司章程和公司内部管理制度 的各项规定；半年度报告的内容和格式符合中国证监会和上海证券交易所的各项规 定，所包含的信息从各个方面真实地反映出公司 2025 年上半年的经营成果和财务状 况等事项；未发现参与 2025 年半年度报告编制和审议的人员有违反保密规定的行为。 所的公告》） 昆药集团股份有限公司监事会 于上海证券交易所网站 www.sse.com.cn） 同意： ...

Core Viewpoint - China Resources Pharmaceutical (03320) reported a decline in revenue and net profit for Kunming Pharmaceutical Group in the first half of 2025, indicating potential challenges in the company's financial performance [1] Financial Performance - Total revenue for the first half of 2025 was approximately 3.351 billion yuan, representing a year-on-year decrease of 11.68% [1] - Net profit attributable to shareholders was about 198 million yuan, down 26.88% year-on-year [1] - Basic earnings per share were reported at 0.26 yuan [1]